These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1518262)

  • 1. [German multicenter thalassemia study. Concept and initial results].
    Kohne E; Stahnke K; Kulozik AE; Kleihauer E
    Klin Padiatr; 1992; 204(4):258-63. PubMed ID: 1518262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
    Cario H; Stahnke K; Kohne E
    Klin Padiatr; 1999; 211(6):431-7. PubMed ID: 10592921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
    Dahlui M; Hishamshah MI; Rahman AJ; Aljunid SM
    Singapore Med J; 2009 Aug; 50(8):794-9. PubMed ID: 19710979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Blood Disorders Survey in the Sultanate of Oman.
    Al-Riyami A; Ebrahim GJ
    J Trop Pediatr; 2003 Jul; 49 Suppl 1():i1-20. PubMed ID: 12934793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beta-pancreatic function in subjects with thalassemia. A 4-year follow-up].
    Zanini R; Briante G; Cantone P; Sticca M; Grasso U
    Pediatr Med Chir; 1985; 7(5):749-53. PubMed ID: 3915549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
    Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
    Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron chelating therapy in thalassemia: current problems.
    Russo G
    Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract]   [Full Text] [Related]  

  • 12. [Transfusion requirements and mean annual hemoglobin level in thalassemia major].
    Brunengo MA; Girot R
    Nouv Rev Fr Hematol (1978); 1986; 28(5):309-13. PubMed ID: 3808940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thalassaemia intermedia. Clinical and laboratory study. Therapeutic suggestions (author's transl)].
    Triadou P; Girot R; Lapoumeroulie C; Pomarede R; Constant S
    Nouv Presse Med; 1982 Jan; 11(4):253-6. PubMed ID: 6173844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rise in haemoglobin levels may enhance serum triiodothyronine (T3). Concentrations in prepubertal patients with beta-thalassaemia major.
    Celani MF; Corradini MC; Rota C; Massolo F
    Exp Clin Endocrinol; 1990 Nov; 96(2):169-76. PubMed ID: 2129031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recommendations for therapy of juvenile thalassemia major].
    Siller V; Frank M
    Fortschr Med; 1980 Nov; 98(44):1720-9. PubMed ID: 7007189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
    Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
    Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model.
    Chan GC; Ng DM; Fong DY; Ha SY; Lau YL
    Am J Hematol; 2004 Aug; 76(4):398-404. PubMed ID: 15282678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ocular findings in Desferal therapy].
    Dennerlein JA; Lang GE; Stahnke K; Kleihauer E; Lang GK
    Ophthalmologe; 1995 Feb; 92(1):38-42. PubMed ID: 7719074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.